Stacey B. Trooskin, MD, PhD, MPH
Executive Medical Officer
Medical and Behavioral Health Programs
Mazzoni Center
Philadelphia, PA

Target Audience

This educational initiative is intended for primary care clinicians, community treaters, hepatologists, gastroenterologists, infectious disease specialists and other healthcare providers currently treating HCV.

Learning Objectives

Upon completion of this program, participants will be better able to:

  • Describe the benefits of peer navigation services and its implications to the success of HCV treatment

  • Evaluate peer navigation support needs and capacities within the practice setting

  • Evaluate the potential for coordination of SUD services and HCV-related peer navigation services

Program Description

Every step in the HCV care continuum for people who inject drugs (PWID) is subject to significant patient attrition. Multiple studies have demonstrated this phenomenon known as the care cascade, which, ultimately, results in a small fraction of HCV-positive persons receiving DAA therapy. However, peer-navigation support services have been shown to increase the number of patients who initiate and complete antiviral HCV therapy and increase the proportion of PWID who engage in substance use disorder (SUD) services. This informational module is intended to improve learner awareness of the role and value of peer navigation services and encourage learners to evaluate their own patient-support needs and capacities. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Integritas Communications. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Purdue University College of Pharmacy designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement 

Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge-based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): 0018-9999-23-017-H011-P, 0.25 contact hour (0.025 CEU). Release: 05/26/2023  Expiration: 05/25/2024

Nurses Accreditation Statement

Purdue University Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. 

This program has been approved for 0.25 contact hour.  

Disclosure of Conflict of Interest

To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships occurring within the past 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity.

Stacey B. Trooskin, MD, PhD, MPH: Grants/Research Support/Advisory Board: Gilead Sciences, Inc.

All relevant conflicts of interest have been mitigated prior to the start of the activity. 

None of the planners, reviewers, Integritas staff, and Purdue University College of Pharmacy staff have relevant financial relationship(s) with ineligible companies to disclose unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Purdue University College of Pharmacy and Integritas Communications do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


In order to receive CME credits, participants must complete the pre-assessment questions, post-test, and program evaluation. Participants must also score at least 70% on the posttest. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

For information about the accreditation of this program, please contact Dawn Sinclair at Purdue University College of Pharmacy at sinclaid@purdue.edu or 765-494-5457. For questions regarding pharmacy CE credit and reports please contact: pharmacy-cecr@purdue.edu.

Fee Information

There is no fee for this educational activity.

Begin Activity
available resources
interactive presentation
linked resources
Suggested Reading
Meeting Series


Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV